论文部分内容阅读
目的探讨美托洛尔联合曲美他嗪对急性心肌梗死(AMI)患者心率变异性(HRV)的影响。方法选取2014年1月—2016年1月在南充市中心医院住院确诊的AMI患者96例,按随机顺序将患者分为M组46例和L组50例。两组患者均给予规范化AMI治疗,在此基础上,M组给予美托洛尔治疗,L组给予曲美他嗪联合美托洛尔治疗。治疗前后分别记录24h动态心电图(holter),评价患者HRV指标变化及不良反应发生情况。结果治疗前两组患者SDNN、SDANN、r MSSD、PNN50比较,差异无统计学意义(P>0.05);治疗后M组SDNN、SDANN、r MSSD、PNN50低于L组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论美托洛尔联合曲美他嗪可以提高AMI患者的HRV,从而减少AMI患者由于HRV降低而再发的严重心血管事件。
Objective To investigate the effect of metoprolol combined with trimetazidine on heart rate variability (HRV) in patients with acute myocardial infarction (AMI). Methods A total of 96 patients with AMI diagnosed in Nanchong Central Hospital from January 2014 to January 2016 were selected and randomly divided into 46 patients in M group and 50 patients in L group. Both groups were given standardized AMI treatment, on the basis of metoprolol in group M and trimetazidine in combination with metoprolol in group L. Before and after treatment were recorded 24 hours Holter, evaluation of HRV index changes and adverse reactions. Results There was no significant difference in SDNN, SDANN, MSSD and PNN50 between the two groups before treatment (P> 0.05). After treatment, the levels of SDNN, SDANN, MSSD and PNN50 in M group were lower than those in L group P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Metoprolol combined with trimetazidine improves HRV in patients with AMI and thus reduces the severity of cardiovascular events in patients with AMI due to reduced HRV.